Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Senicapoc in Patients With Progressive Fibrotic ILD (Interstitial Lung Disease) and IPF (Idiopathic Pulmonary Fibrosis) to Prevent Progression.

NCT06714123 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT06714123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06714123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Senicapoc in Patients With Progressive Fibrotic ILD (Interstitial Lung Disease) and IPF (Idiopathic Pulmonary Fibrosis) to Prevent Progression.
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
December 31, 2028
Enrollment
140 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, pulmonary fibrosis, interstitial lung disease